| |
September 8-11, 2025 | Philadelphia, PA Join the industry's top minds at Fierce Pharma Week—where innovation, strategy, and partnerships converge. Don’t miss your chance to lead the future of pharma. Register Today. 
|
|
Today’s Big NewsJul 1, 2025 |
|
Thursday, July 22, 2025 | 10am ET / 7am PT Join us to take an exciting look at the forefront of REMS transformation. Learn how leading technology, integrated strategies and operational excellence are redefining what’s possible. Gain the insights you need to reduce complexity, enhance compliance and deliver more value across the REMS lifecycle. Register now. 
|
|
| By James Waldron Argenx wants to get in on the macrocyclic peptide action, penning a deal worth $1.5 billion in biobucks with Californian biotech Unnatural Products to hunt down “undruggable” targets. |
|
|
|
By Nick Paul Taylor Oncternal Therapeutics’ ROR1 programs have gone out with a whimper, offloaded to Ho’ola Therapeutics for $3 million upfront as the biotech winds down its operations. |
By Gabrielle Masson Apple Tree Partners’ life sciences venture fund has filed litigation against its controlling limited partners, claiming the investor has failed to meet its monetary commitments and warning of immediate consequences for its biotech portfolio. |
Sponsored by Invest Puerto Rico With decades of excellence in biosciences, Invest PR’s CEO shares how the island is uniquely positioned to lead the reshoring movement. |
|
Discover how flow chemistry can revolutionize your chemical processes and position your business for long-term success. This insightful whitepaper explores how flow chemistry is transforming pharmaceutical manufacturing, significantly reducing waste and energy consumption. Download now. 
|
|
By James Waldron Beckley Psytech’s psychedelic drug has successfully reduced the symptoms of depression in a phase 2 study, triggering the biotech’s merger with mental health-focused atai Life Sciences. |
By Gabrielle Masson Concentra Biosciences continues to scavenge for struggling biotechs, this time picking up antibody biotech IGM Biosciences for $1.25 per share. |
By James Waldron Fosun Pharma subsidiary Henlius Biotech is paying $10 million upfront for regional rights to HanchorBio’s phase 2 CD47 blocker. |
By James Waldron BerGenBio, reeling from the failure of its lead cancer drug, has opted to merge with fellow Norwegian cancer biotech Oncoinvent. |
By Nick Paul Taylor Sanofi has doubled down on its partnership with Adagene, investing $25 million in the biotech, taking up its option on a third program and agreeing to sponsor a trial of its partner’s lead candidate. |
By Zoey Becker The U.S. Supreme Court ruled to protect a measure of the Affordable Care Act that supports preventative services such as pre-exposure prophylaxis (PrEP) HIV meds, offering good news for Gilead as it launches its long-acting PrEP drug Yeztugo. |
By Dave Muoio The takedown includes charges against 29 individuals alleged to be participating in transnational criminal organizations, who law enforcement said submitted more than $12 billion in fraudulent claims. |
By Paige Minemyer More than 100,000 individuals may have been impacted by a "data incident" where unauthorized Medicare beneficiary accounts were made using their information. |
Fierce podcasts Don’t miss an episode |
| In this episode of "The Top Line," Teva CEO Richard Francis shares progress on the company’s “Pivot to Growth” strategy and what lies ahead. |
|
|---|
|
|
|
Now Available On-Demand Access this deep dive to gain valuable insights and guidance from leading industry experts on diagnostic and precision medicine testing. Register now. 
|
|
Whitepaper Presented by Blue Matter, strategic consultants in the life sciences Sponsored by Blue Matter Consulting |
Executive Summary Biotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster. Sponsored by: IQVIA Laboratories |
Whitepaper We analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| Deadline Extended: July 2 |
|
| Sheraton Philadelphia Downtown |
|
|
| |
|
